TY - JOUR
T1 - Feasibility, safety, and effectiveness of transcranial direct current stimulation for decreasing post-ERCP pain
T2 - A randomized, sham-controlled, pilot study
AU - Borckardt, Jeffrey J.
AU - Romagnuolo, Joseph
AU - Reeves, Scott T.
AU - Madan, Alok
AU - Frohman, Heather
AU - Beam, Will
AU - George, Mark S.
PY - 2011/6
Y1 - 2011/6
N2 - Background: Emerging evidence shows that transcranial direct current stimulation (tDCS), a minimally invasive brain stimulation technique, has analgesic effects in chronic pain patients and in healthy volunteers with experimental pain. No studies have examined the analgesic effects of tDCS immediately after surgical/endoscopic procedures. Endoscopy investigating abdominal pain, especially ERCP, can cause significant postprocedural pain. Objective: To test the feasibility, efficacy, and safety of tDCS on post-ERCP pain and analgesia use. Design: Randomized, sham-controlled, pilot study. Setting: Tertiary-care medical center. Patients: This study involved 21 patients who were hospitalized overnight for ERCP for unexplained right upper quadrant pain. Intervention: Twenty minutes of real 2.0 mA tDCS or sham (anode over left prefrontal cortex; cathode over gut-representation of right sensory cortex) immediately after ERCP. Main Outcome Measurements: Pain (visual analogue scale, McGill pain questionnaire, brief pain inventory), patient-controlled analgesia use, adverse events. Results: Real tDCS was associated with 22% less total hydromorphone use, versus sham. The slope of the cumulative patient-controlled analgesia usage curve was significantly steeper in the sham tDCS group (F [2,13] = 15.96; P = .0003). Real tDCS patients reported significantly less pain interference with sleep (t [17] = 3.70; P = .002) and less throbbing pain (t [16] = 2.37; P = .03). Visual analogue scale pain and mood scores (4 hours post-ERCP) suggested a nonsignificant advantage for real tDCS, despite less hydromorphone use. Side effects of tDCS were limited to mild, self-limited tingling, itching, and stinging under electrodes. Limitations: Small sample size, variability in chronic pain, and chronic opioid use. Conclusion: In this pilot study, tDCS appears to be safe, has minimal side effects, and may reduce postprocedural analgesia requirements and subjective pain ratings. Future studies appear warranted.
AB - Background: Emerging evidence shows that transcranial direct current stimulation (tDCS), a minimally invasive brain stimulation technique, has analgesic effects in chronic pain patients and in healthy volunteers with experimental pain. No studies have examined the analgesic effects of tDCS immediately after surgical/endoscopic procedures. Endoscopy investigating abdominal pain, especially ERCP, can cause significant postprocedural pain. Objective: To test the feasibility, efficacy, and safety of tDCS on post-ERCP pain and analgesia use. Design: Randomized, sham-controlled, pilot study. Setting: Tertiary-care medical center. Patients: This study involved 21 patients who were hospitalized overnight for ERCP for unexplained right upper quadrant pain. Intervention: Twenty minutes of real 2.0 mA tDCS or sham (anode over left prefrontal cortex; cathode over gut-representation of right sensory cortex) immediately after ERCP. Main Outcome Measurements: Pain (visual analogue scale, McGill pain questionnaire, brief pain inventory), patient-controlled analgesia use, adverse events. Results: Real tDCS was associated with 22% less total hydromorphone use, versus sham. The slope of the cumulative patient-controlled analgesia usage curve was significantly steeper in the sham tDCS group (F [2,13] = 15.96; P = .0003). Real tDCS patients reported significantly less pain interference with sleep (t [17] = 3.70; P = .002) and less throbbing pain (t [16] = 2.37; P = .03). Visual analogue scale pain and mood scores (4 hours post-ERCP) suggested a nonsignificant advantage for real tDCS, despite less hydromorphone use. Side effects of tDCS were limited to mild, self-limited tingling, itching, and stinging under electrodes. Limitations: Small sample size, variability in chronic pain, and chronic opioid use. Conclusion: In this pilot study, tDCS appears to be safe, has minimal side effects, and may reduce postprocedural analgesia requirements and subjective pain ratings. Future studies appear warranted.
UR - http://www.scopus.com/inward/record.url?scp=79957858078&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79957858078&partnerID=8YFLogxK
U2 - 10.1016/j.gie.2011.01.050
DO - 10.1016/j.gie.2011.01.050
M3 - Article
C2 - 21470608
AN - SCOPUS:79957858078
SN - 0016-5107
VL - 73
SP - 1158
EP - 1164
JO - Gastrointestinal Endoscopy
JF - Gastrointestinal Endoscopy
IS - 6
ER -